Mast cell disease is a group of conditions in which mast cells, a type of immune cell found throughout your body, either grow in abnormal numbers or release their chemical contents too easily and too often. These cells normally help defend against parasites and coordinate allergic responses, but when they malfunction, the flood of chemicals they release can cause symptoms across nearly every organ system. Mast cell disease affects roughly 10 to 27 people per 100,000, making it rare but increasingly recognized.
How Mast Cells Work and What Goes Wrong
Mast cells live in your skin, gut lining, airways, and connective tissues. They act like chemical alarm systems. When they detect a threat, they undergo a process called degranulation: bursting open to release a cocktail of inflammatory substances including histamine, tryptase, heparin, and prostaglandins. Histamine is the one most people know from allergies. It causes blood vessels to widen, skin to itch, and stomach acid to increase. Tryptase drives inflammation in surrounding tissues, causes airway constriction, and promotes fluid leakage from small blood vessels.
In mast cell disease, this alarm system is stuck in overdrive. Depending on the specific condition, the problem may be that mast cells accumulate in tissues where they don’t belong, that they degranulate in response to minor or harmless triggers, or both.
The Three Main Types
The World Health Organization divides mast cell disease into three broad categories: cutaneous mastocytosis, systemic mastocytosis, and mast cell activation syndrome (MCAS). A fourth category, mast cell sarcoma, exists but is extremely rare.
Cutaneous Mastocytosis
This form is limited to the skin. It’s more common in children and often appears as reddish-brown spots or patches that itch or swell when rubbed. Many children with cutaneous mastocytosis improve or fully resolve by puberty. In adults, the condition tends to persist but usually doesn’t progress to more serious forms.
Systemic Mastocytosis
Systemic mastocytosis means mast cells have accumulated in internal organs, most commonly the bone marrow but also the liver, spleen, and gastrointestinal tract. A Danish nationwide study found the combined prevalence of systemic mastocytosis to be about 11 per 100,000 people. The most common subtype, indolent systemic mastocytosis, progresses slowly and carries a near-normal life expectancy. Advanced forms, including aggressive systemic mastocytosis and mast cell leukemia, involve organ damage and require more intensive treatment.
More than 90% of people with mastocytosis carry a specific genetic mutation called KIT D816V. This mutation causes the receptor on the surface of mast cells to stay permanently switched on, driving the cells to multiply and survive longer than they should. The mutation is acquired during a person’s lifetime rather than inherited from parents, appearing in roughly 85 to 90% of adult cases.
Mast Cell Activation Syndrome
MCAS is different from mastocytosis. The mast cells aren’t necessarily growing out of control in number. Instead, they’re releasing their chemical contents too aggressively. Diagnosis requires meeting three criteria: episodic symptoms affecting two or more organ systems that are consistent with mast cell mediator release, measurable elevation of a mast cell marker (usually tryptase in the blood) during a symptomatic episode, and improvement of symptoms with medications that block or reduce mast cell mediators.
MCAS itself splits into subtypes. Primary MCAS involves clonal (genetically abnormal) mast cells. Secondary MCAS is driven by an underlying condition like a severe allergy. Idiopathic MCAS is diagnosed when neither clonal cells nor another trigger can be found.
Symptoms Across the Body
Because mast cells live in so many tissues, the symptoms of mast cell disease can mimic dozens of other conditions. This is a major reason diagnosis is often delayed. The most frequent symptoms include flushing, itching, diarrhea, and anaphylaxis, but the full picture is much broader.
Skin symptoms are the most visible: hives, flushing, swelling, and intense itching. Gastrointestinal problems are common too, including abdominal pain, nausea, vomiting, diarrhea, and in some cases peptic ulcers or gastrointestinal bleeding. Cardiovascular episodes can involve sudden drops in blood pressure, fainting, and rapid heart rate. Respiratory involvement may show up as wheezing or nasal congestion.
One of the less recognized categories is neuropsychiatric symptoms. Depression, difficulty concentrating, short-term memory problems, irritability, and mood swings are commonly reported in adults with mastocytosis. These symptoms are sometimes grouped under the term “mixed organic brain syndrome” and likely stem from the effects of mast cell chemicals on the nervous system. Fatigue and excessive sleepiness round out the picture, and for many patients these cognitive and emotional symptoms are among the most disabling.
Acute episodes of widespread mediator release can progress to anaphylaxis, with flushing, gastrointestinal distress, and vascular collapse occurring together. Anaphylaxis can happen in both cutaneous and systemic mastocytosis.
How It’s Diagnosed
Diagnosing mast cell disease involves blood tests, sometimes urine tests, and for systemic mastocytosis, a bone marrow biopsy. The most important blood marker is baseline serum tryptase. A level above 20 ng/mL meets one of the minor diagnostic criteria for systemic mastocytosis. Levels above 200 ng/mL indicate more severe disease burden. For MCAS, doctors look for a rise in tryptase during a symptomatic flare compared to the patient’s own baseline, documented on at least two separate occasions.
A normal tryptase level does not rule out mast cell disease. The likelihood of finding characteristic clusters of mast cells on a bone marrow biopsy drops significantly when tryptase is below 20 ng/mL, but it remains possible. Genetic testing for the KIT D816V mutation is another important piece of the puzzle, and detection rates range from 30% to 95% depending on how sensitive the testing method is. Tryptase can also be elevated in other blood disorders, so the diagnosis always involves looking at the whole clinical picture rather than relying on a single lab result.
Common Triggers
People with mast cell disease learn that certain exposures can set off a cascade of symptoms. Identifying and avoiding personal triggers is considered the cornerstone of management. Common ones include:
- Insect stings and animal venoms, which are among the most dangerous triggers and a frequent cause of severe anaphylaxis in this population
- Temperature extremes, both heat and cold
- Mechanical irritation of the skin, such as friction, pressure, or rubbing
- Alcohol
- Certain medications, including aspirin, some anesthetic agents, and radiocontrast dyes used in imaging scans
- Emotional stress and physical exertion
Triggers vary widely between individuals, and what causes a severe reaction in one person may be completely tolerated by another.
Treatment and Symptom Management
Treatment for mast cell disease focuses on two goals: reducing the chemical load from overactive mast cells and, in advanced forms, controlling abnormal mast cell growth.
For the majority of patients with indolent disease or MCAS, daily medications target the chemicals mast cells release. H1 antihistamines (like cetirizine, loratadine, or fexofenadine) address itching, hives, and flushing. H2 antihistamines reduce stomach acid and help with gastrointestinal symptoms. Many patients take both types daily. Mast cell stabilizers work by blocking a calcium channel that mast cells need in order to degranulate, essentially keeping them from dumping their contents. Cromolyn sodium is the most commonly used stabilizer and is particularly helpful for gut symptoms. Leukotriene blockers, like montelukast, target another inflammatory pathway downstream of mast cell activation and can help with both respiratory and gastrointestinal complaints.
The fact that symptoms improve with these anti-mediator therapies is itself part of the diagnostic criteria for MCAS. If a combination of antihistamines, mast cell stabilizers, or leukotriene blockers meaningfully reduces your symptoms, it supports the diagnosis.
For advanced systemic mastocytosis, where organ damage is occurring, treatment shifts toward drugs that target the abnormal mast cells themselves. The FDA approved midostaurin in 2017 for aggressive systemic mastocytosis, systemic mastocytosis with an associated blood disorder, and mast cell leukemia. This drug works by blocking the overactive KIT receptor that drives mast cell growth. In clinical trials, overall response rates ranged from 50% to 75% depending on the subtype. More recently, newer and more selective KIT inhibitors have expanded the treatment options for both advanced and indolent forms of the disease.
Everyone with mast cell disease should carry injectable epinephrine for emergency use, given the risk of anaphylaxis. Wearing medical identification that notes the condition helps emergency responders provide appropriate care quickly.